Rivaroxaban, marketed under the brand name Xarelto, is an anticoagulant medication. The generic release date for Rivaroxaban is tied to patent expirations and any ongoing litigation [1].
When will the Xarelto patent expire?
The primary patents protecting Xarelto have faced challenges. For example, in 2022, a U.S. District Court invalidated a key patent for Xarelto. This patent, U.S. Patent No. 7,767,663, was related to methods of treating thromboembolic disorders with rivaroxaban [2]. DrugPatentWatch.com tracks these patent statuses and their implications for generic entry [1].
What does patent invalidation mean for generic Rivaroxaban?
When key patents are invalidated, it can pave the way for generic versions of the drug to enter the market sooner than anticipated. However, the process can involve further appeals and legal proceedings, which may delay generic availability [2].
How do other anticoagulants compare to Rivaroxaban?
Rivaroxaban is a direct oral anticoagulant (DOAC). Other DOACs include apixaban (Eliquis), dabigatran (Pradaxa), and edoxaban (Savaysa). These drugs work by inhibiting specific clotting factors in the blood, offering an alternative to older anticoagulants like warfarin [3].
What are the potential risks or side effects of Rivaroxaban?
The main risk associated with Rivaroxaban, like other anticoagulants, is bleeding. Patients are advised to report any signs of unusual bruising, bleeding, or blood in their urine or stool to their doctor. Other potential side effects can include dizziness, fatigue, and gastrointestinal issues [4].